Maprotiline drug information

Why is this medication prescribed?
How should this medicine be used?
Other uses for this medicine
What special precautions should I follow?
What special dietary instructions should I follow?
What should I do if I forget a dose?
What side effects can this medication cause?
What should I know about STORAGE and DISPOSAL of this medication?
What should I do in case of OVERDOSE?
What OTHER INFORMATION should I know?
Drug interactions

IMPORTANT WARNING

A small number of children, teenagers, and young adults (up to 24 years of age) who took antidepressants ('mood elevators') such as maprotiline during clinical studies became suicidal (thinking about harming or killing oneself or planning or trying to do so). Children, teenagers, and young adults who take antidepressants to treat depression or other mental illnesses may be more likely to become suicidal than children, teenagers, and young adults who do not take antidepressants to treat these conditions. However, experts are not sure about how great this risk is and how much it should be considered in deciding whether a child or teenager should take an antidepressant. Children younger than 18 years of age should not normally take maprotiline, but in some cases, a doctor may decide that maprotiline is the best medication to treat a child's condition.

You should know that your mental health may change in unexpected ways when you take maprotiline or other antidepressants even if you are an adult over 24 years of age. You may become suicidal, especially at the beginning of your treatment and any time that your dose is increased or decreased. You, your family, or your caregiver should call your doctor right away if you experience any of the following symptoms: new or worsening depression; thinking about harming or killing yourself, or planning or trying to do so; extreme worry; agitation; panic attacks; difficulty falling asleep or staying asleep; aggressive behavior; irritability; acting without thinking; severe restlessness; and frenzied abnormal excitement. Be sure that your family or caregiver knows which symptoms may be serious so they can call the doctor if you are unable to seek treatment on your own.

Your healthcare provider will want to see you often while you are taking maprotiline, especially at the beginning of your treatment. Be sure to keep all appointments for office visits with your doctor.

The doctor or pharmacist will give you the manufacturer's patient information sheet (medication guide) when you begin treatment with maprotiline. Read the information carefully and ask your doctor or pharmacist if you have any questions. You also can obtain the Medication Guide from the FDA website: http://www.fda.gov/Drugs/DrugSafety/ucm085729.htm.

No matter what your age, before you take an antidepressant, you, your parent, or your caregiver should talk to your doctor about the risks and benefits of treating your condition with an antidepressant or with other treatments. You should also talk about the risks and benefits of not treating your condition. You should know that having depression or another mental illness greatly increases the risk that you will become suicidal. This risk is higher if you or anyone in your family has or has ever had bipolar disorder (mood that changes from depressed to abnormally excited) or mania (frenzied, abnormally excited mood) or has thought about or attempted suicide. Talk to your doctor about your condition, symptoms, and personal and family medical history. You and your doctor will decide what type of treatment is right for you.

Why is this medication prescribed?

Maprotiline is used to treat depression, bipolar disorder (manic depressive disorder; a disease that causes episodes of depression, episodes of mania, and other abnormal moods), and anxiety. Maprotiline is in a class of medications called tetracyclic antidepressants. It works by increasing the amounts of certain natural substances in the brain that are needed to maintain mental balance.

How should this medicine be used?

Maprotiline comes as a tablet to take by mouth. It is usually taken one to three times a day and may be taken with or without food. Take maprotiline at around the same time(s) every day. Follow the directions on your prescription label carefully, and ask your doctor or pharmacist to explain any part you do not understand. Take maprotiline exactly as directed. Do not take more or less of it or take it more often than prescribed by your doctor.

It may take a few weeks or longer for you to feel the full benefit of maprotiline. Continue to take maprotiline even if you feel well. Do not stop taking maprotiline without talking to your doctor. Your doctor will probably want to decrease your dose gradually.

Other uses for this medicine

This medication may be prescribed for other uses. Ask your doctor or pharmacist for more information.

What special precautions should I follow?

Before taking maprotiline,

tell your doctor and pharmacist if you are allergic to maprotiline or any other medications.

tell your doctor if you are taking a monoamine oxidase (MAO) inhibitor such as isocarboxazid (Marplan), phenelzine (Nardil), selegiline (Eldepryl, Emsam, Zelapar), and tranylcypromine (Parnate), or if you have taken an MAO inhibitor during the past 14 days. Your doctor will probably tell you that you should not take maprotiline.

tell your doctor and pharmacist what prescription and nonprescription medications, vitamins, nutritional supplements and herbal products you are taking or plan to take. Be sure to mention any of the following: anticoagulants (blood thinners) such as warfarin (Coumadin); antihistamines; estrogens; fluoxetine (Prozac); levodopa (Sinemet, Larodopa); lithium (Eskalith, Lithobid); medication for high blood pressure, seizures, Parkinson's disease, asthma, colds, or allergies; methylphenidate (Ritalin); muscle relaxants; oral contraceptives; sedatives; sleeping pills; thyroid medication; and tranquilizers. Your doctor may need to change the doses of your medications or monitor you carefully for side effects.

tell your doctor if you have or have ever had glaucoma (an eye condition), an enlarged prostate (a male reproductive gland), difficulty urinating, seizures, a brain tumor, a head injury, an overactive thyroid gland, or liver, kidney, or heart disease.

tell your doctor if you are pregnant, plan to become pregnant, or are breast-feeding. If you become pregnant while taking maprotiline, call your doctor.

if you are having surgery, including dental surgery, tell the doctor or dentist that you are taking maprotiline.

you should know that this medication may make you drowsy. Do not drive a car or operate machinery until you know how this medication affects you.

remember that alcohol can add to the drowsiness caused by this medication.

tell your doctor if you use tobacco products. Cigarette smoking may decrease the effectiveness of this medication.

What special dietary instructions should I follow?

Unless your doctor tells you otherwise, continue your normal diet.

What should I do if I forget a dose?

Take the missed dose as soon as you remember it. However, if it is almost time for your next dose, skip the missed dose and continue your regular dosing schedule. Do not take a double dose to make up for a missed one.

What side effects can this medication cause?

Maprotiline may cause side effects. Tell your doctor if any of these symptoms are severe or do not go away:
- nausea
- drowsiness
- weakness or tiredness
- nightmares
- dry mouth
- skin more sensitive to sunlight than usual
- changes in appetite or weight
- constipation
- difficulty urinating
- frequent urination
- blurred vision
- changes in sex drive or ability
- excessive sweating

Some side effects can be serious. If you experience any of the following symptoms or those listed in the IMPORTANT WARNING section, call your doctor immediately:
- jaw, neck, and back muscle spasms
- slow or difficult speech
- shuffling walk
- uncontrollable shaking of a part of the body
- fever, chills, sore throat, or flu-like symptoms
- difficulty breathing or swallowing
- rash
- yellowing of the skin or eyes
- irregular heartbeat
Maprotiline may cause other side effects. Call your doctor if you have any unusual problems while you are taking this medication.
If you experience a serious side effect, you or your doctor may send a report to the Food and Drug Administration's (FDA) MedWatch Adverse Event Reporting program online (http://www.fda.gov/Safety/MedWatch) or by phone (1-800-332-1088).

What should I know about STORAGE and DISPOSAL of this medication?

Keep this medication in the container it came in, tightly closed, and out of reach of children. Store it at room temperature and away from excess heat and moisture (not in the bathroom).

Unneeded medications should be disposed of in special ways to ensure that pets, children, and other people cannot consume them. However, you should not flush this medication down the toilet. Instead, the best way to dispose of your medication is through a medicine take-back program. Talk to your pharmacist or contact your local garbage/recycling department to learn about take-back programs in your community. See the FDA's Safe Disposal of Medicines website (http://goo.gl/c4Rm4p) for more information if you do not have access to a take-back program.

It is important to keep all medication out of sight and reach of children as many containers (such as weekly pill minders and those for eye drops, creams, patches, and inhalers) are not child-resistant and young children can open them easily. To protect young children from poisoning, always lock safety caps and immediately place the medication in a safe location – one that is up and away and out of their sight and reach. http://www.upandaway.org

What should I do in case of OVERDOSE?

In case of overdose, call the poison control helpline at 1-800-222-1222. Information is also available online at https://www.poisonhelp.org/help. If the victim has collapsed, had a seizure, has trouble breathing, or can't be awakened, immediately call emergency services at 911.

What OTHER INFORMATION should I know?

Keep all appointments with your doctor and the laboratory. Your doctor will order certain lab tests to check your response to maprotiline.

Do not let anyone else take your medication. Ask your pharmacist any questions you have about refilling your prescription.

It is important for you to keep a written list of all of the prescription and nonprescription (over-the-counter) medicines you are taking, as well as any products such as vitamins, minerals, or other dietary supplements. You should bring this list with you each time you visit a doctor or if you are admitted to a hospital. It is also important information to carry with you in case of emergencies.

Drug interactions

Drug	Interaction
Moxifloxacin	Moxifloxacin The metabolism of Maprotiline can be decreased when combined with Moxifloxacin.
Insulin Glargine (rDNA origin) Injection	Insulin Glargine (rDNA origin) Injection The metabolism of Maprotiline can be increased when combined with Insulin glargine.
Leflunomide	Leflunomide The serum concentration of Maprotiline can be decreased when it is combined with Leflunomide.
Delavirdine	Delavirdine The metabolism of Maprotiline can be decreased when combined with Delavirdine.
Nevirapine	Nevirapine The metabolism of Maprotiline can be decreased when combined with Nevirapine.
Dolasetron	Dolasetron The risk or severity of adverse effects can be increased when Dolasetron is combined with Maprotiline.
Aminophylline	Aminophylline The metabolism of Aminophylline can be decreased when combined with Maprotiline.
Anagrelide	Anagrelide The risk or severity of QTc prolongation can be increased when Maprotiline is combined with Anagrelide.
Bisacodyl	Bisacodyl The therapeutic efficacy of Bisacodyl can be decreased when used in combination with Maprotiline.
Cilostazol	Cilostazol The metabolism of Cilostazol can be decreased when combined with Maprotiline.
Clopidogrel	Clopidogrel The metabolism of Maprotiline can be decreased when combined with Clopidogrel.
Diphenoxylate	Diphenoxylate The risk or severity of adverse effects can be increased when Maprotiline is combined with Diphenoxylate.
Erythromycin and Sulfisoxazole	Erythromycin and Sulfisoxazole The risk or severity of QTc prolongation can be increased when Maprotiline is combined with Erythromycin.
Estrogen and Progestin (Oral Contraceptives)	Estrogen and Progestin (Oral Contraceptives) The metabolism of Maprotiline can be decreased when combined with Conjugated estrogens.
Fenofibrate	Fenofibrate Maprotiline may decrease the excretion rate of Fenofibrate which could result in a higher serum level.
Guanfacine	Guanfacine Guanfacine may increase the central nervous system depressant (CNS depressant) activities of Maprotiline.
Magnesium Hydroxide	Magnesium Hydroxide Maprotiline may decrease the excretion rate of Magnesium hydroxide which could result in a higher serum level.
Magnesium Oxide	Magnesium Oxide The therapeutic efficacy of Magnesium oxide can be decreased when used in combination with Maprotiline.
Mycophenolate	Mycophenolate Maprotiline may decrease the excretion rate of Mycophenolic acid which could result in a higher serum level.
Naratriptan	Naratriptan The risk or severity of adverse effects can be increased when Maprotiline is combined with Naratriptan.
Olsalazine	Olsalazine Olsalazine may decrease the excretion rate of Maprotiline which could result in a higher serum level.
Paregoric	Paregoric The risk or severity of adverse effects can be increased when Morphine is combined with Maprotiline.
Penbutolol	Penbutolol The risk or severity of QTc prolongation can be increased when Maprotiline is combined with Acebutolol.
Pentazocine	Pentazocine The risk or severity of adverse effects can be increased when Pentazocine is combined with Maprotiline.
Polyethylene glycol-electrolyte solution (PEG-ES)	Polyethylene glycol-electrolyte solution (PEG-ES) The therapeutic efficacy of Polyethylene glycol can be decreased when used in combination with Maprotiline.
Potassium	Potassium Potassium may increase the excretion rate of Maprotiline which could result in a lower serum level and potentially a reduction in efficacy.
Prednisone	Prednisone Prednisone may decrease the excretion rate of Maprotiline which could result in a higher serum level.
Psyllium	Psyllium The therapeutic efficacy of Plantago seed can be decreased when used in combination with Maprotiline.
Ranitidine	Ranitidine The metabolism of Maprotiline can be decreased when combined with Ranitidine.
Reserpine	Reserpine The risk or severity of adverse effects can be increased when Reserpine is combined with Maprotiline.
Rizatriptan	Rizatriptan Maprotiline may increase the central nervous system depressant (CNS depressant) activities of Rizatriptan.
Sumatriptan	Sumatriptan Sumatriptan may increase the central nervous system depressant (CNS depressant) activities of Maprotiline.
Tacrolimus	Tacrolimus Tacrolimus may decrease the excretion rate of Maprotiline which could result in a higher serum level.
Tizanidine	Tizanidine Tizanidine may increase the central nervous system depressant (CNS depressant) activities of Maprotiline.
Zolmitriptan	Zolmitriptan The metabolism of Maprotiline can be decreased when combined with Zolmitriptan.
Ampicillin Injection	Ampicillin Injection Ampicillin may decrease the excretion rate of Maprotiline which could result in a higher serum level.
Doxycycline Injection	Doxycycline Injection Doxycycline may decrease the excretion rate of Maprotiline which could result in a higher serum level.
Famotidine Injection	Famotidine Injection The risk or severity of QTc prolongation can be increased when Famotidine is combined with Maprotiline.
Fluconazole Injection	Fluconazole Injection The risk or severity of QTc prolongation can be increased when Fluconazole is combined with Maprotiline.
Foscarnet Injection	Foscarnet Injection Foscarnet may decrease the excretion rate of Maprotiline which could result in a higher serum level.
Hydromorphone Injection	Hydromorphone Injection The risk or severity of adverse effects can be increased when Hydromorphone is combined with Maprotiline.
Interferon Beta-1b Injection	Interferon Beta-1b Injection The metabolism of Maprotiline can be decreased when combined with Interferon beta-1b.
Interferon Gamma-1b Injection	Interferon Gamma-1b Injection The metabolism of Maprotiline can be decreased when combined with Interferon gamma-1b.
Levofloxacin Injection	Levofloxacin Injection The risk or severity of QTc prolongation can be increased when Maprotiline is combined with Levofloxacin.
Meperidine Injection	Meperidine Injection The risk or severity of adverse effects can be increased when Maprotiline is combined with Meperidine.
Metoclopramide Injection	Metoclopramide Injection The risk or severity of sedation can be increased when Maprotiline is combined with Metoclopramide.
Metronidazole Injection	Metronidazole Injection The risk or severity of QTc prolongation can be increased when Metronidazole is combined with Maprotiline.
Morphine Injection	Morphine Injection The risk or severity of adverse effects can be increased when Morphine is combined with Maprotiline.
Pamidronate Injection	Pamidronate Injection Pamidronic acid may decrease the excretion rate of Maprotiline which could result in a higher serum level.
Vancomycin Injection	Vancomycin Injection Maprotiline may decrease the excretion rate of Vancomycin which could result in a higher serum level.
Altretamine	Altretamine Amphetamine may decrease the sedative and stimulatory activities of Maprotiline.
Cefuroxime	Cefuroxime Cefuroxime may decrease the excretion rate of Maprotiline which could result in a higher serum level.
Cyclosporine	Cyclosporine The metabolism of Maprotiline can be decreased when combined with Cyclosporine.
Ondansetron	Ondansetron The risk or severity of adverse effects can be increased when Ondansetron is combined with Maprotiline.
Granisetron	Granisetron The risk or severity of adverse effects can be increased when Granisetron is combined with Maprotiline.
Torsemide	Torsemide Torasemide may increase the excretion rate of Maprotiline which could result in a lower serum level and potentially a reduction in efficacy.
Olanzapine	Olanzapine The risk or severity of adverse effects can be increased when Olanzapine is combined with Maprotiline.
Alosetron	Alosetron The metabolism of Maprotiline can be decreased when combined with Alosetron.
Dofetilide	Dofetilide The risk or severity of QTc prolongation can be increased when Maprotiline is combined with Dofetilide.
Entacapone	Entacapone Entacapone may increase the central nervous system depressant (CNS depressant) activities of Maprotiline.
Hydroxychloroquine	Hydroxychloroquine The metabolism of Maprotiline can be decreased when combined with Hydroxychloroquine.
Meloxicam	Meloxicam Meloxicam may decrease the excretion rate of Maprotiline which could result in a higher serum level.
Oxcarbazepine	Oxcarbazepine Oxcarbazepine may increase the central nervous system depressant (CNS depressant) activities of Maprotiline.
Pantoprazole	Pantoprazole Pantoprazole may decrease the excretion rate of Maprotiline which could result in a higher serum level.
Temozolomide	Temozolomide Temozolomide may decrease the excretion rate of Maprotiline which could result in a higher serum level.
Zaleplon	Zaleplon Zaleplon may increase the central nervous system depressant (CNS depressant) activities of Maprotiline.
Anakinra	Anakinra The metabolism of Maprotiline can be increased when combined with Anakinra.
Desloratadine	Desloratadine Maprotiline may increase the central nervous system depressant (CNS depressant) activities of Desloratadine.
Linezolid	Linezolid The risk or severity of serotonin syndrome can be increased when Linezolid is combined with Maprotiline.
Rivastigmine	Rivastigmine The therapeutic efficacy of Maprotiline can be decreased when used in combination with Rivastigmine.
Trimipramine	Trimipramine The metabolism of Maprotiline can be decreased when combined with Trimipramine.
Etanercept Injection	Etanercept Injection The metabolism of Maprotiline can be increased when combined with Etanercept.
Glycopyrrolate	Glycopyrrolate The risk or severity of adverse effects can be increased when Maprotiline is combined with Glycopyrronium.
Modafinil	Modafinil The metabolism of Maprotiline can be increased when combined with Modafinil.
Perindopril	Perindopril Perindopril may decrease the excretion rate of Maprotiline which could result in a higher serum level.
Tenofovir	Tenofovir Tenofovir may decrease the excretion rate of Maprotiline which could result in a higher serum level.
Choline Magnesium Trisalicylate	Choline Magnesium Trisalicylate Choline magnesium trisalicylate may decrease the excretion rate of Maprotiline which could result in a higher serum level.
Epinephrine Injection	Epinephrine Injection The risk or severity of Tachycardia can be increased when Epinephrine is combined with Maprotiline.
Eplerenone	Eplerenone Eplerenone may increase the excretion rate of Maprotiline which could result in a lower serum level and potentially a reduction in efficacy.
Escitalopram	Escitalopram The risk or severity of serotonin syndrome can be increased when Maprotiline is combined with Escitalopram.
Zonisamide	Zonisamide Zonisamide may increase the central nervous system depressant (CNS depressant) activities of Maprotiline.
Adalimumab Injection	Adalimumab Injection The metabolism of Maprotiline can be increased when combined with Adalimumab.
Aripiprazole	Aripiprazole The risk or severity of adverse effects can be increased when Maprotiline is combined with Aripiprazole.
Atomoxetine	Atomoxetine The risk or severity of adverse effects can be increased when Atomoxetine is combined with Maprotiline.
Dexmethylphenidate	Dexmethylphenidate The risk or severity of adverse effects can be increased when Maprotiline is combined with Dexmethylphenidate.
Atazanavir	Atazanavir Atazanavir may decrease the excretion rate of Maprotiline which could result in a higher serum level.
Almotriptan	Almotriptan Almotriptan may increase the central nervous system depressant (CNS depressant) activities of Maprotiline.
Eletriptan	Eletriptan The risk or severity of adverse effects can be increased when Eletriptan is combined with Maprotiline.
Mefloquine	Mefloquine The risk or severity of QTc prolongation can be increased when Mefloquine is combined with Maprotiline.
Polyethylene Glycol 3350	Polyethylene Glycol 3350 The therapeutic efficacy of Polyethylene glycol can be decreased when used in combination with Maprotiline.
Vardenafil	Vardenafil The risk or severity of QTc prolongation can be increased when Vardenafil is combined with Maprotiline.
Alfuzosin	Alfuzosin The risk or severity of QTc prolongation can be increased when Alfuzosin is combined with Maprotiline.
Emtricitabine	Emtricitabine Emtricitabine may decrease the excretion rate of Maprotiline which could result in a higher serum level.
Interferon Beta-1a Subcutaneous Injection	Interferon Beta-1a Subcutaneous Injection The metabolism of Maprotiline can be decreased when combined with Interferon beta-1a.
Memantine	Memantine The therapeutic efficacy of Maprotiline can be decreased when used in combination with Memantine.
Tegaserod	Tegaserod The metabolism of Maprotiline can be decreased when combined with Tegaserod.
Tadalafil	Tadalafil Tadalafil may decrease the excretion rate of Maprotiline which could result in a higher serum level.
Frovatriptan	Frovatriptan The metabolism of Frovatriptan can be decreased when combined with Maprotiline.
Gemifloxacin	Gemifloxacin The risk or severity of QTc prolongation can be increased when Maprotiline is combined with Gemifloxacin.
Progesterone	Progesterone The metabolism of Maprotiline can be decreased when combined with Progesterone.
Apomorphine Injection	Apomorphine Injection The risk or severity of adverse effects can be increased when Apomorphine is combined with Maprotiline.
Infliximab Injection	Infliximab Injection The metabolism of Maprotiline can be increased when combined with Infliximab.
Protriptyline	Protriptyline Protriptyline may increase the central nervous system depressant (CNS depressant) activities of Maprotiline.
Duloxetine	Duloxetine The metabolism of Maprotiline can be decreased when combined with Duloxetine.
Tinidazole	Tinidazole Tinidazole may decrease the excretion rate of Maprotiline which could result in a higher serum level.
Trospium	Trospium Maprotiline may increase the central nervous system depressant (CNS depressant) activities of Trospium.
Cefditoren	Cefditoren Cefdinir may decrease the excretion rate of Maprotiline which could result in a higher serum level.
Cinacalcet	Cinacalcet The metabolism of Maprotiline can be decreased when combined with Cinacalcet.
Cyanocobalamin Injection	Cyanocobalamin Injection Hydroxocobalamin may decrease the excretion rate of Maprotiline which could result in a higher serum level.
Erlotinib	Erlotinib The metabolism of Erlotinib can be decreased when combined with Maprotiline.
Eszopiclone	Eszopiclone The risk or severity of CNS depression can be increased when Maprotiline is combined with Eszopiclone.
Ganciclovir	Ganciclovir Maprotiline may decrease the excretion rate of Ganciclovir which could result in a higher serum level.
Ribavirin	Ribavirin Ribavirin may decrease the excretion rate of Maprotiline which could result in a higher serum level.
Solifenacin	Solifenacin Maprotiline may increase the central nervous system depressant (CNS depressant) activities of Solifenacin.
Valganciclovir	Valganciclovir Maprotiline may decrease the excretion rate of Valganciclovir which could result in a higher serum level.
Voriconazole	Voriconazole The risk or severity of QTc prolongation can be increased when Voriconazole is combined with Maprotiline.
Adefovir	Adefovir Adefovir may decrease the excretion rate of Maprotiline which could result in a higher serum level.
Dextroamphetamine	Dextroamphetamine Amphetamine may decrease the sedative and stimulatory activities of Maprotiline.
Entecavir	Entecavir The metabolism of Maprotiline can be decreased when combined with Entecavir.
Peginterferon Alfa-2a Injection	Peginterferon Alfa-2a Injection The metabolism of Maprotiline can be decreased when combined with Peginterferon alfa-2a.
Peginterferon Alfa-2b (PEG-Intron)	Peginterferon Alfa-2b (PEG-Intron) The serum concentration of Maprotiline can be increased when it is combined with Peginterferon alfa-2b.
Pramlintide Injection	Pramlintide Injection The risk or severity of reduced gastrointestinal motility can be increased when Pramlintide is combined with Maprotiline.
Sodium Oxybate	Sodium Oxybate Sodium oxybate may increase the central nervous system depressant (CNS depressant) activities of Maprotiline.
Ibandronate	Ibandronate The risk or severity of QTc prolongation can be increased when Ibandronate is combined with Maprotiline.
Isocarboxazid	Isocarboxazid The risk or severity of adverse effects can be increased when Maprotiline is combined with Isocarboxazid.
Ramelteon	Ramelteon Ramelteon may increase the central nervous system depressant (CNS depressant) activities of Maprotiline.
Darifenacin	Darifenacin The metabolism of Maprotiline can be decreased when combined with Darifenacin.
Fentanyl	Fentanyl The risk or severity of adverse effects can be increased when Maprotiline is combined with Fentanyl.
Pregabalin	Pregabalin The therapeutic efficacy of Maprotiline can be increased when used in combination with Pregabalin.
Deferasirox	Deferasirox The serum concentration of Maprotiline can be increased when it is combined with Deferasirox.
Phenylephrine	Phenylephrine The metabolism of Maprotiline can be increased when combined with Phenylephrine.
Tipranavir	Tipranavir The metabolism of Maprotiline can be decreased when combined with Tipranavir.
Felbamate	Felbamate Felbamate may increase the central nervous system depressant (CNS depressant) activities of Maprotiline.
Ranolazine	Ranolazine The serum concentration of Maprotiline can be increased when it is combined with Ranolazine.
Abatacept Injection	Abatacept Injection The metabolism of Maprotiline can be increased when combined with Abatacept.
Rasagiline	Rasagiline The risk or severity of adverse effects can be increased when Rasagiline is combined with Maprotiline.
Imatinib	Imatinib The risk or severity of QTc prolongation can be increased when Maprotiline is combined with Imatinib.
Sitagliptin	Sitagliptin Maprotiline may decrease the excretion rate of Sitagliptin which could result in a higher serum level.
Varenicline	Varenicline Maprotiline may decrease the excretion rate of Varenicline which could result in a higher serum level.
Gefitinib	Gefitinib The metabolism of Maprotiline can be decreased when combined with Gefitinib.
Albuterol	Albuterol The risk or severity of QTc prolongation can be increased when Maprotiline is combined with Salbutamol.
Paliperidone	Paliperidone The risk or severity of adverse effects can be increased when Maprotiline is combined with Paliperidone.
Bortezomib	Bortezomib The metabolism of Maprotiline can be decreased when combined with Bortezomib.
Clofarabine Injection	Clofarabine Injection Clofarabine may decrease the excretion rate of Maprotiline which could result in a higher serum level.
Insulin Glulisine (rDNA origin) Injection	Insulin Glulisine (rDNA origin) Injection The metabolism of Maprotiline can be increased when combined with Insulin glulisine.
Lubiprostone	Lubiprostone Maprotiline may decrease the excretion rate of Lubiprostone which could result in a higher serum level.
Oxaliplatin Injection	Oxaliplatin Injection The risk or severity of QTc prolongation can be increased when Maprotiline is combined with Oxaliplatin.
Posaconazole	Posaconazole The risk or severity of QTc prolongation can be increased when Maprotiline is combined with Posaconazole.
Primaquine	Primaquine The metabolism of Primaquine can be decreased when combined with Maprotiline.
Pemetrexed Injection	Pemetrexed Injection Maprotiline may decrease the excretion rate of Pemetrexed which could result in a higher serum level.
Dimenhydrinate	Dimenhydrinate Dimenhydrinate may increase the central nervous system depressant (CNS depressant) activities of Maprotiline.
Lisdexamfetamine	Lisdexamfetamine Lisdexamfetamine may decrease the sedative and stimulatory activities of Maprotiline.
Nabilone	Nabilone Nabilone may increase the central nervous system depressant (CNS depressant) activities of Maprotiline.
Vorinostat	Vorinostat The risk or severity of QTc prolongation can be increased when Maprotiline is combined with Vorinostat.
Sorafenib	Sorafenib The metabolism of Maprotiline can be decreased when combined with Sorafenib.
Sunitinib	Sunitinib The risk or severity of QTc prolongation can be increased when Maprotiline is combined with Sunitinib.
Dronabinol	Dronabinol Dronabinol may increase the central nervous system depressant (CNS depressant) activities of Maprotiline.
Lapatinib	Lapatinib The risk or severity of QTc prolongation can be increased when Maprotiline is combined with Lapatinib.
Levocetirizine	Levocetirizine Levocetirizine may increase the central nervous system depressant (CNS depressant) activities of Maprotiline.
Pegaptanib Injection	Pegaptanib Injection Maprotiline may decrease the excretion rate of Pegaptanib which could result in a higher serum level.
Dasatinib	Dasatinib The metabolism of Dasatinib can be decreased when combined with Maprotiline.
Mexiletine	Mexiletine The metabolism of Maprotiline can be decreased when combined with Mexiletine.
Armodafinil	Armodafinil The metabolism of Maprotiline can be increased when combined with Armodafinil.
Azacitidine Injection	Azacitidine Injection Azacitidine may decrease the excretion rate of Maprotiline which could result in a higher serum level.
Paclitaxel (with polyoxyethylated castor oil) Injection	Paclitaxel (with polyoxyethylated castor oil) Injection The therapeutic efficacy of Castor oil can be decreased when used in combination with Maprotiline.
Temsirolimus	Temsirolimus The metabolism of Maprotiline can be decreased when combined with Temsirolimus.
Lenalidomide	Lenalidomide Lenalidomide may decrease the excretion rate of Maprotiline which could result in a higher serum level.
Nilotinib	Nilotinib The metabolism of Nilotinib can be decreased when combined with Maprotiline.
Toremifene	Toremifene The risk or severity of QTc prolongation can be increased when Maprotiline is combined with Toremifene.
Budesonide	Budesonide Maprotiline may decrease the excretion rate of Budesonide which could result in a higher serum level.
Desmopressin	Desmopressin Desmopressin may decrease the excretion rate of Maprotiline which could result in a higher serum level.
Betaine	Betaine The therapeutic efficacy of Maprotiline can be decreased when used in combination with Glycine betaine.
OnabotulinumtoxinA Injection	OnabotulinumtoxinA Injection The risk or severity of adverse effects can be increased when Maprotiline is combined with Botulinum toxin type A.
RimabotulinumtoxinB Injection	RimabotulinumtoxinB Injection The risk or severity of adverse effects can be increased when Maprotiline is combined with Botulinum Toxin Type B.
Doripenem Injection	Doripenem Injection Maprotiline may decrease the excretion rate of Doripenem which could result in a higher serum level.
Arsenic Trioxide Injection	Arsenic Trioxide Injection The risk or severity of QTc prolongation can be increased when Maprotiline is combined with Arsenic trioxide.
Desvenlafaxine	Desvenlafaxine The risk or severity of adverse effects can be increased when Maprotiline is combined with Desvenlafaxine.
Cevimeline	Cevimeline Cevimeline may decrease the excretion rate of Maprotiline which could result in a higher serum level.
Nebivolol	Nebivolol The metabolism of Nebivolol can be decreased when combined with Maprotiline.
Bendamustine Injection	Bendamustine Injection The metabolism of Bendamustine can be decreased when combined with Maprotiline.
Flecainide	Flecainide The metabolism of Flecainide can be decreased when combined with Maprotiline.
Certolizumab Injection	Certolizumab Injection The metabolism of Maprotiline can be increased when combined with Certolizumab pegol.
Daptomycin Injection	Daptomycin Injection Daptomycin may decrease the excretion rate of Maprotiline which could result in a higher serum level.
Praziquantel	Praziquantel The metabolism of Praziquantel can be decreased when combined with Maprotiline.
Methylnaltrexone Injection	Methylnaltrexone Injection Maprotiline may decrease the excretion rate of Methylnaltrexone which could result in a higher serum level.
Rufinamide	Rufinamide The risk or severity of adverse effects can be increased when Rufinamide is combined with Maprotiline.
Midazolam	Midazolam The risk or severity of adverse effects can be increased when Midazolam is combined with Maprotiline.
Naltrexone Injection	Naltrexone Injection The risk or severity of adverse effects can be increased when Naltrexone is combined with Maprotiline.
Dexrazoxane Injection	Dexrazoxane Injection Dexrazoxane may decrease the excretion rate of Maprotiline which could result in a higher serum level.
Eltrombopag	Eltrombopag The metabolism of Eltrombopag can be decreased when combined with Maprotiline.
Milnacipran	Milnacipran The risk or severity of adverse effects can be increased when Maprotiline is combined with Milnacipran.
Plerixafor Injection	Plerixafor Injection Maprotiline may decrease the excretion rate of Plerixafor which could result in a higher serum level.
Sodium Phosphate	Sodium Phosphate The therapeutic efficacy of Sodium phosphate, monobasic can be decreased when used in combination with Maprotiline.
Fesoterodine	Fesoterodine Maprotiline may increase the central nervous system depressant (CNS depressant) activities of Fesoterodine.
Degarelix Injection	Degarelix Injection The risk or severity of QTc prolongation can be increased when Maprotiline is combined with Degarelix.
Betaxolol	Betaxolol The risk or severity of QTc prolongation can be increased when Maprotiline is combined with Betaxolol.
Iloperidone	Iloperidone The risk or severity of adverse effects can be increased when Maprotiline is combined with Iloperidone.
Prasugrel	Prasugrel Maprotiline may decrease the excretion rate of Prasugrel which could result in a higher serum level.
Lacosamide	Lacosamide Lacosamide may increase the central nervous system depressant (CNS depressant) activities of Maprotiline.
Everolimus	Everolimus The metabolism of Maprotiline can be decreased when combined with Everolimus.
Tolvaptan (low blood sodium)	Tolvaptan (low blood sodium) Tolvaptan may increase the excretion rate of Maprotiline which could result in a lower serum level and potentially a reduction in efficacy.
Dronedarone	Dronedarone The metabolism of Dronedarone can be decreased when combined with Maprotiline.
AbobotulinumtoxinA Injection	AbobotulinumtoxinA Injection The risk or severity of adverse effects can be increased when Maprotiline is combined with Botulinum toxin type A.
Pralatrexate Injection	Pralatrexate Injection Maprotiline may decrease the excretion rate of Pralatrexate which could result in a higher serum level.
Palonosetron Injection	Palonosetron Injection Palonosetron may increase the central nervous system depressant (CNS depressant) activities of Maprotiline.
Saxagliptin	Saxagliptin Maprotiline may decrease the excretion rate of Saxagliptin which could result in a higher serum level.
Telavancin Injection	Telavancin Injection The risk or severity of QTc prolongation can be increased when Maprotiline is combined with Telavancin.
Romidepsin Injection	Romidepsin Injection The risk or severity of QTc prolongation can be increased when Maprotiline is combined with Romidepsin.
Tapentadol	Tapentadol Tapentadol may increase the central nervous system depressant (CNS depressant) activities of Maprotiline.
Topotecan	Topotecan Maprotiline may decrease the excretion rate of Topotecan which could result in a higher serum level.
Golimumab Injection	Golimumab Injection The metabolism of Maprotiline can be increased when combined with Golimumab.
Pazopanib	Pazopanib The risk or severity of QTc prolongation can be increased when Maprotiline is combined with Pazopanib.
Asenapine	Asenapine The risk or severity of adverse effects can be increased when Maprotiline is combined with Asenapine.
Vigabatrin	Vigabatrin Vigabatrin may increase the central nervous system depressant (CNS depressant) activities of Maprotiline.
Albendazole	Albendazole The metabolism of Maprotiline can be decreased when combined with Albendazole.
Oxymorphone	Oxymorphone The risk or severity of adverse effects can be increased when Maprotiline is combined with Oxymorphone.
Tocilizumab Injection	Tocilizumab Injection The metabolism of Maprotiline can be increased when combined with Tocilizumab.
Dalfampridine	Dalfampridine The risk or severity of seizure can be increased when Maprotiline is combined with Dalfampridine.
Eribulin Injection	Eribulin Injection The risk or severity of QTc prolongation can be increased when Maprotiline is combined with Eribulin.
IncobotulinumtoxinA Injection	IncobotulinumtoxinA Injection The risk or severity of adverse effects can be increased when Maprotiline is combined with Botulinum toxin type A.
Ceftaroline Injection	Ceftaroline Injection Ceftaroline fosamil may decrease the excretion rate of Maprotiline which could result in a higher serum level.
Lurasidone	Lurasidone The risk or severity of adverse effects can be increased when Maprotiline is combined with Lurasidone.
Acetaminophen Injection	Acetaminophen Injection The metabolism of Maprotiline can be decreased when combined with Acetaminophen.
Vilazodone	Vilazodone The metabolism of Vilazodone can be decreased when combined with Maprotiline.
Ipilimumab Injection	Ipilimumab Injection Maprotiline may decrease the excretion rate of Ipilimumab which could result in a higher serum level.
Denileukin Diftitox Injection	Denileukin Diftitox Injection Aldesleukin may decrease the excretion rate of Maprotiline which could result in a higher serum level.
Terbutaline Injection	Terbutaline Injection The risk or severity of QTc prolongation can be increased when Terbutaline is combined with Maprotiline.
Roflumilast	Roflumilast Maprotiline may decrease the excretion rate of Roflumilast which could result in a higher serum level.
Rilpivirine	Rilpivirine The metabolism of Maprotiline can be decreased when combined with Rilpivirine.
Abiraterone	Abiraterone The serum concentration of Maprotiline can be increased when it is combined with Abiraterone.
Triptorelin Injection	Triptorelin Injection The risk or severity of QTc prolongation can be increased when Maprotiline is combined with Triptorelin.
Rivaroxaban	Rivaroxaban Maprotiline may decrease the excretion rate of Rivaroxaban which could result in a higher serum level.
Ruxolitinib	Ruxolitinib Maprotiline may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.
Vandetanib	Vandetanib The risk or severity of QTc prolongation can be increased when Maprotiline is combined with Vandetanib.
Clobazam	Clobazam The metabolism of Maprotiline can be decreased when combined with Clobazam.
Vemurafenib	Vemurafenib The serum concentration of Maprotiline can be increased when it is combined with Vemurafenib.
Deferiprone	Deferiprone Maprotiline may decrease the excretion rate of Deferiprone which could result in a higher serum level.
Axitinib	Axitinib The metabolism of Axitinib can be decreased when combined with Maprotiline.
Crizotinib	Crizotinib The risk or severity of QTc prolongation can be increased when Maprotiline is combined with Crizotinib.
Cabergoline	Cabergoline The risk or severity of adverse effects can be increased when Cabergoline is combined with Maprotiline.
Naloxone Injection	Naloxone Injection Maprotiline may decrease the excretion rate of Naloxone which could result in a higher serum level.
Fondaparinux Injection	Fondaparinux Injection Fondaparinux may decrease the excretion rate of Maprotiline which could result in a higher serum level.
Ezogabine	Ezogabine Tiagabine may increase the central nervous system depressant (CNS depressant) activities of Maprotiline.
Enzalutamide	Enzalutamide Maprotiline may decrease the excretion rate of Enzalutamide which could result in a higher serum level.
Mirabegron	Mirabegron The risk or severity of urinary retention can be increased when Maprotiline is combined with Mirabegron.
Linaclotide	Linaclotide The therapeutic efficacy of Linaclotide can be decreased when used in combination with Maprotiline.
Teriflunomide	Teriflunomide The serum concentration of Maprotiline can be decreased when it is combined with Teriflunomide.
Teduglutide Injection	Teduglutide Injection Maprotiline may decrease the excretion rate of Teduglutide which could result in a higher serum level.
Bedaquiline	Bedaquiline The risk or severity of QTc prolongation can be increased when Maprotiline is combined with Bedaquiline.
Alogliptin	Alogliptin Maprotiline may decrease the excretion rate of Alogliptin which could result in a higher serum level.
Ponatinib	Ponatinib The metabolism of Ponatinib can be decreased when combined with Maprotiline.
Pomalidomide	Pomalidomide Pomalidomide may increase the central nervous system depressant (CNS depressant) activities of Maprotiline.
Canagliflozin	Canagliflozin Maprotiline may increase the excretion rate of Canagliflozin which could result in a lower serum level and potentially a reduction in efficacy.
Methazolamide	Methazolamide Methazolamide may increase the excretion rate of Maprotiline which could result in a lower serum level and potentially a reduction in efficacy.
Dabrafenib	Dabrafenib The risk or severity of QTc prolongation can be increased when Maprotiline is combined with Dabrafenib.
Ospemifene	Ospemifene The metabolism of Maprotiline can be decreased when combined with Ospemifene.
Trametinib	Trametinib Maprotiline may decrease the excretion rate of Trametinib which could result in a higher serum level.
Levomilnacipran	Levomilnacipran The risk or severity of adverse effects can be increased when Maprotiline is combined with Levomilnacipran.
Ertapenem Injection	Ertapenem Injection Ertapenem may decrease the excretion rate of Maprotiline which could result in a higher serum level.
Vortioxetine	Vortioxetine The risk or severity of adverse effects can be increased when Maprotiline is combined with Vortioxetine.
Perampanel	Perampanel Perampanel may increase the central nervous system depressant (CNS depressant) activities of Maprotiline.
Ibrutinib	Ibrutinib The metabolism of Ibrutinib can be decreased when combined with Maprotiline.
Ketorolac Injection	Ketorolac Injection Ketorolac may decrease the excretion rate of Maprotiline which could result in a higher serum level.
Simeprevir	Simeprevir The metabolism of Maprotiline can be decreased when combined with Simeprevir.
Sofosbuvir	Sofosbuvir Maprotiline may decrease the excretion rate of Sofosbuvir which could result in a higher serum level.
Dapagliflozin	Dapagliflozin The metabolism of Maprotiline can be decreased when combined with Dapagliflozin.
Apremilast	Apremilast The metabolism of Maprotiline can be increased when combined with Apremilast.
Droxidopa	Droxidopa Maprotiline may decrease the excretion rate of Droxidopa which could result in a higher serum level.
Ceritinib	Ceritinib The risk or severity of QTc prolongation can be increased when Maprotiline is combined with Ceritinib.
Siltuximab Injection	Siltuximab Injection The metabolism of Maprotiline can be increased when combined with Siltuximab.
Eslicarbazepine	Eslicarbazepine Eslicarbazepine may increase the central nervous system depressant (CNS depressant) activities of Maprotiline.
Belinostat Injection	Belinostat Injection The metabolism of Maprotiline can be increased when combined with Belinostat.
Testosterone Injection	Testosterone Injection Testosterone may decrease the excretion rate of Maprotiline which could result in a higher serum level.
Oritavancin Injection	Oritavancin Injection The metabolism of Maprotiline can be decreased when combined with Oritavancin.
Hydrocodone	Hydrocodone Hydrocodone may increase the central nervous system depressant (CNS depressant) activities of Maprotiline.
Suvorexant	Suvorexant Maprotiline may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.
Edoxaban	Edoxaban Maprotiline may decrease the excretion rate of Edoxaban which could result in a higher serum level.
Peginterferon Beta-1a Injection	Peginterferon Beta-1a Injection The metabolism of Maprotiline can be decreased when combined with Peginterferon beta-1a.
Methamphetamine	Methamphetamine Metamfetamine may decrease the sedative and stimulatory activities of Maprotiline.
Tasimelteon	Tasimelteon Tasimelteon may increase the central nervous system depressant (CNS depressant) activities of Maprotiline.
Pirfenidone	Pirfenidone The metabolism of Pirfenidone can be decreased when combined with Maprotiline.
Secukinumab Injection	Secukinumab Injection The metabolism of Maprotiline can be increased when combined with Secukinumab.
Risperidone Injection	Risperidone Injection The risk or severity of adverse effects can be increased when Risperidone is combined with Maprotiline.
Insulin Human Inhalation	Insulin Human Inhalation The metabolism of Maprotiline can be increased when combined with Insulin human.
Lenvatinib	Lenvatinib The risk or severity of QTc prolongation can be increased when Maprotiline is combined with Lenvatinib.
Naloxegol	Naloxegol The metabolism of Maprotiline can be decreased when combined with Naloxegol.
Panobinostat	Panobinostat The metabolism of Maprotiline can be decreased when combined with Panobinostat.
Haloperidol Injection	Haloperidol Injection The risk or severity of QTc prolongation can be increased when Haloperidol is combined with Maprotiline.
Ivabradine	Ivabradine The risk or severity of QTc prolongation can be increased when Maprotiline is combined with Ivabradine.
Amiloride	Amiloride Amiloride may increase the excretion rate of Maprotiline which could result in a lower serum level and potentially a reduction in efficacy.
Macitentan	Macitentan Maprotiline may decrease the excretion rate of Macitentan which could result in a higher serum level.
Flibanserin	Flibanserin The risk or severity of adverse effects can be increased when Maprotiline is combined with Flibanserin.
Rolapitant	Rolapitant The metabolism of Maprotiline can be decreased when combined with Rolapitant.
Brexpiprazole	Brexpiprazole The risk or severity of adverse effects can be increased when Maprotiline is combined with Brexpiprazole.
Ziprasidone Injection	Ziprasidone Injection The risk or severity of QTc prolongation can be increased when Ziprasidone is combined with Maprotiline.
Cariprazine	Cariprazine The risk or severity of adverse effects can be increased when Maprotiline is combined with Cariprazine.
Penicillin G Procaine Injection	Penicillin G Procaine Injection Maprotiline may decrease the excretion rate of Procaine benzylpenicillin which could result in a higher serum level.
Eluxadoline	Eluxadoline The risk or severity of constipation can be increased when Maprotiline is combined with Eluxadoline.
Insulin Degludec (rDNA Origin) Injection	Insulin Degludec (rDNA Origin) Injection The metabolism of Maprotiline can be increased when combined with Insulin degludec.
Trabectedin Injection	Trabectedin Injection The metabolism of Trabectedin can be decreased when combined with Maprotiline.
Osimertinib	Osimertinib The serum concentration of Maprotiline can be decreased when it is combined with Osimertinib.
Ixazomib	Ixazomib Maprotiline may decrease the excretion rate of Ixazomib which could result in a higher serum level.
Lesinurad	Lesinurad Maprotiline may decrease the excretion rate of Lesinurad which could result in a higher serum level.
Amphotericin B Liposomal Injection	Amphotericin B Liposomal Injection Amphotericin B may decrease the excretion rate of Maprotiline which could result in a higher serum level.
Brivaracetam Injection	Brivaracetam Injection Brivaracetam may increase the central nervous system depressant (CNS depressant) activities of Maprotiline.
Cobicistat	Cobicistat The metabolism of Maprotiline can be decreased when combined with Cobicistat.
Midodrine	Midodrine The risk or severity of Tachycardia can be increased when Midodrine is combined with Maprotiline.
Pimavanserin	Pimavanserin The risk or severity of adverse effects can be increased when Maprotiline is combined with Pimavanserin.
Obeticholic Acid	Obeticholic Acid The metabolism of Maprotiline can be decreased when combined with Obeticholic acid.
Diphenhydramine Injection	Diphenhydramine Injection The risk or severity of adverse effects can be increased when Maprotiline is combined with Diphenhydramine.
Furosemide Injection	Furosemide Injection Furosemide may increase the excretion rate of Maprotiline which could result in a lower serum level and potentially a reduction in efficacy.
Rucaparib	Rucaparib The metabolism of Rucaparib can be decreased when combined with Maprotiline.
Lixisenatide Injection	Lixisenatide Injection Maprotiline may decrease the excretion rate of Lixisenatide which could result in a higher serum level.
Ribociclib	Ribociclib The risk or severity of QTc prolongation can be increased when Maprotiline is combined with Ribociclib.
Doxepin (Insomnia)	Doxepin (Insomnia) Maprotiline may increase the central nervous system depressant (CNS depressant) activities of Doxepin.
Plecanatide	Plecanatide The therapeutic efficacy of Plecanatide can be decreased when used in combination with Maprotiline.
Deutetrabenazine	Deutetrabenazine The risk or severity of QTc prolongation can be increased when Maprotiline is combined with Deutetrabenazine.
Valbenazine	Valbenazine Maprotiline may decrease the excretion rate of Valbenazine which could result in a higher serum level.
Safinamide	Safinamide The risk or severity of adverse effects can be increased when Safinamide is combined with Maprotiline.
Naldemedine	Naldemedine Maprotiline may decrease the excretion rate of Naldemedine which could result in a higher serum level.
Midostaurin	Midostaurin The metabolism of Maprotiline can be decreased when combined with Midostaurin.
Enasidenib	Enasidenib The metabolism of Maprotiline can be decreased when combined with Enasidenib.
Benznidazole	Benznidazole Maprotiline may decrease the excretion rate of Benznidazole which could result in a higher serum level.
Delafloxacin	Delafloxacin The risk or severity of QTc prolongation can be increased when Maprotiline is combined with Delafloxacin.
Letermovir	Letermovir The metabolism of Letermovir can be decreased when combined with Maprotiline.
Tetrabenazine	Tetrabenazine The risk or severity of QTc prolongation can be increased when Maprotiline is combined with Tetrabenazine.
Ertugliflozin	Ertugliflozin Ertugliflozin may increase the excretion rate of Maprotiline which could result in a lower serum level and potentially a reduction in efficacy.
Buprenorphine Injection	Buprenorphine Injection Maprotiline may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.
Apalutamide	Apalutamide Maprotiline may decrease the excretion rate of Apalutamide which could result in a higher serum level.
Baricitinib	Baricitinib Maprotiline may decrease the excretion rate of Baricitinib which could result in a higher serum level.
Lofexidine	Lofexidine The therapeutic efficacy of Maprotiline can be increased when used in combination with Lofexidine.
Plazomicin Injection	Plazomicin Injection Maprotiline may decrease the excretion rate of Plazomicin which could result in a higher serum level.
Eliglustat	Eliglustat The risk or severity of QTc prolongation can be increased when Maprotiline is combined with Eliglustat.
Encorafenib	Encorafenib The risk or severity of QTc prolongation can be increased when Maprotiline is combined with Encorafenib.
Binimetinib	Binimetinib The metabolism of Binimetinib can be decreased when combined with Maprotiline.
Ivosidenib	Ivosidenib The risk or severity of QTc prolongation can be increased when Maprotiline is combined with Ivosidenib.
Elagolix	Elagolix The metabolism of Elagolix can be decreased when combined with Maprotiline.
Tafenoquine	Tafenoquine The metabolism of Tafenoquine can be decreased when combined with Maprotiline.
Cannabidiol	Cannabidiol The risk or severity of adverse effects can be increased when Cannabidiol is combined with Maprotiline.
Dacomitinib	Dacomitinib The metabolism of Maprotiline can be decreased when combined with Dacomitinib.
Stiripentol	Stiripentol The metabolism of Maprotiline can be decreased when combined with Stiripentol.
Gilteritinib	Gilteritinib The therapeutic efficacy of Maprotiline can be decreased when used in combination with Gilteritinib.
Glasdegib	Glasdegib The risk or severity of QTc prolongation can be increased when Maprotiline is combined with Glasdegib.
Rifamycin	Rifamycin The metabolism of Maprotiline can be decreased when combined with Rifamycin.
Prucalopride	Prucalopride Maprotiline may decrease the excretion rate of Prucalopride which could result in a higher serum level.
Magnesium Citrate	Magnesium Citrate The therapeutic efficacy of Magnesium citrate can be decreased when used in combination with Maprotiline.
Emapalumab-lzsg Injection	Emapalumab-lzsg Injection The metabolism of Maprotiline can be increased when combined with Emapalumab.
Acyclovir Ophthalmic	Acyclovir Ophthalmic Acyclovir may decrease the excretion rate of Maprotiline which could result in a higher serum level.
Brexanolone Injection	Brexanolone Injection Brexanolone may increase the central nervous system depressant (CNS depressant) activities of Maprotiline.
Solriamfetol	Solriamfetol The risk or severity of Tachycardia can be increased when Solriamfetol is combined with Maprotiline.
Triclabendazole	Triclabendazole The metabolism of Maprotiline can be decreased when combined with Triclabendazole.
Entrectinib	Entrectinib The risk or severity of QTc prolongation can be increased when Maprotiline is combined with Entrectinib.
Istradefylline	Istradefylline The metabolism of Istradefylline can be decreased when combined with Maprotiline.
Pitolisant	Pitolisant The therapeutic efficacy of Pitolisant can be decreased when used in combination with Maprotiline.
Fedratinib	Fedratinib The metabolism of Maprotiline can be decreased when combined with Fedratinib.
Lefamulin	Lefamulin Lefamulin may increase the QTc-prolonging activities of Maprotiline.
Phenytoin Injection	Phenytoin Injection Phenytoin may increase the central nervous system depressant (CNS depressant) activities of Maprotiline.
Fosphenytoin Injection	Fosphenytoin Injection Fosphenytoin may increase the central nervous system depressant (CNS depressant) activities of Maprotiline.
Lumateperone	Lumateperone Lumateperone may increase the central nervous system depressant (CNS depressant) activities of Maprotiline.
Lasmiditan	Lasmiditan The risk or severity of serotonin syndrome can be increased when Maprotiline is combined with Lasmiditan.
Cenobamate	Cenobamate The therapeutic efficacy of Cenobamate can be decreased when used in combination with Maprotiline.
Selumetinib	Selumetinib The metabolism of Selumetinib can be decreased when combined with Maprotiline.
Capmatinib	Capmatinib The metabolism of Maprotiline can be decreased when combined with Capmatinib.
Lemborexant	Lemborexant Lemborexant may increase the central nervous system depressant (CNS depressant) activities of Maprotiline.
Daratumumab and Hyaluronidase-fihj Injection	Daratumumab and Hyaluronidase-fihj Injection The therapeutic efficacy of Hyaluronidase can be decreased when used in combination with Maprotiline.
Fenfluramine	Fenfluramine The risk or severity of serotonin syndrome can be increased when Fenfluramine is combined with Maprotiline.
Fostemsavir	Fostemsavir The risk or severity of QTc prolongation can be increased when Maprotiline is combined with Fostemsavir.
Pertuzumab, Trastuzumab, and Hyaluronidase-zzxf Injection	Pertuzumab, Trastuzumab, and Hyaluronidase-zzxf Injection The therapeutic efficacy of Hyaluronidase can be decreased when used in combination with Maprotiline.
Octreotide	Octreotide The risk or severity of QTc prolongation can be increased when Octreotide is combined with Maprotiline.
Satralizumab-mwge Injection	Satralizumab-mwge Injection The serum concentration of Maprotiline can be decreased when it is combined with Satralizumab.
Relugolix	Relugolix The risk or severity of QTc prolongation can be increased when Maprotiline is combined with Relugolix.
Progestin-Only (drospirenone) Oral Contraceptives	Progestin-Only (drospirenone) Oral Contraceptives Drospirenone may increase the excretion rate of Maprotiline which could result in a lower serum level and potentially a reduction in efficacy.
Viloxazine	Viloxazine The risk or severity of adverse effects can be increased when Maprotiline is combined with Viloxazine.
Tobramycin Injection	Tobramycin Injection Tobramycin may decrease the excretion rate of Maprotiline which could result in a higher serum level.
Theophylline	Theophylline The metabolism of Theophylline can be decreased when combined with Maprotiline.
Fenoprofen	Fenoprofen Fenoprofen may decrease the excretion rate of Maprotiline which could result in a higher serum level.
Indomethacin	Indomethacin Indomethacin may decrease the excretion rate of Maprotiline which could result in a higher serum level.
Mefenamic Acid	Mefenamic Acid Mefenamic acid may decrease the excretion rate of Maprotiline which could result in a higher serum level.
Naproxen	Naproxen Naproxen may decrease the excretion rate of Maprotiline which could result in a higher serum level.
Tolmetin	Tolmetin Tolmetin may decrease the excretion rate of Maprotiline which could result in a higher serum level.
Sulindac	Sulindac Sulindac may decrease the excretion rate of Maprotiline which could result in a higher serum level.
Trazodone	Trazodone The risk or severity of QTc prolongation can be increased when Trazodone is combined with Maprotiline.
Isotretinoin	Isotretinoin Maprotiline may decrease the excretion rate of Isotretinoin which could result in a higher serum level.
Sucralfate	Sucralfate Sucralfate may decrease the excretion rate of Maprotiline which could result in a higher serum level.
Hydroxyurea	Hydroxyurea The metabolism of Maprotiline can be decreased when combined with Hydroxyurea.
Floxuridine	Floxuridine Floxuridine may decrease the excretion rate of Maprotiline which could result in a higher serum level.
Phenobarbital	Phenobarbital Phenobarbital may increase the central nervous system depressant (CNS depressant) activities of Maprotiline.
Metaxalone	Metaxalone Metaxalone may increase the central nervous system depressant (CNS depressant) activities of Maprotiline.
Methotrexate Injection	Methotrexate Injection Methotrexate may decrease the excretion rate of Maprotiline which could result in a higher serum level.
Levorphanol	Levorphanol The risk or severity of adverse effects can be increased when Levorphanol is combined with Maprotiline.
Primidone	Primidone The metabolism of Maprotiline can be increased when combined with Primidone.
Methsuximide	Methsuximide Methsuximide may increase the central nervous system depressant (CNS depressant) activities of Maprotiline.
Diethylpropion	Diethylpropion Diethylpropion may decrease the sedative and stimulatory activities of Maprotiline.
Chlorpromazine	Chlorpromazine The metabolism of Maprotiline can be decreased when combined with Chlorpromazine.
Diazepam	Diazepam The risk or severity of adverse effects can be increased when Diazepam is combined with Maprotiline.
Oxazepam	Oxazepam The risk or severity of adverse effects can be increased when Oxazepam is combined with Maprotiline.
Flurazepam	Flurazepam The risk or severity of adverse effects can be increased when Flurazepam is combined with Maprotiline.
Clorazepate	Clorazepate The risk or severity of adverse effects can be increased when Clorazepic acid is combined with Maprotiline.
Lorazepam	Lorazepam The risk or severity of adverse effects can be increased when Lorazepam is combined with Maprotiline.
Carmustine	Carmustine The metabolism of Maprotiline can be decreased when combined with Carmustine.
Amantadine	Amantadine The risk or severity of QTc prolongation can be increased when Amantadine is combined with Maprotiline.
Codeine	Codeine The risk or severity of adverse effects can be increased when Maprotiline is combined with Codeine.
Meprobamate	Meprobamate The risk or severity of adverse effects can be increased when Meprobamate is combined with Maprotiline.
Chlordiazepoxide	Chlordiazepoxide The risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Maprotiline.
Bromocriptine	Bromocriptine The risk or severity of adverse effects can be increased when Maprotiline is combined with Bromocriptine.
Metaproterenol	Metaproterenol The risk or severity of Tachycardia can be increased when Orciprenaline is combined with Maprotiline.
Tranylcypromine	Tranylcypromine The metabolism of Maprotiline can be decreased when combined with Tranylcypromine.
Phenelzine	Phenelzine The risk or severity of adverse effects can be increased when Phenelzine is combined with Maprotiline.
Procarbazine	Procarbazine The risk or severity of adverse effects can be increased when Procarbazine is combined with Maprotiline.
Ergoloid Mesylates	Ergoloid Mesylates The risk or severity of adverse effects can be increased when Maprotiline is combined with Ergoloid mesylate.
Tetracycline	Tetracycline Tetracycline may decrease the excretion rate of Maprotiline which could result in a higher serum level.
Minocycline	Minocycline Minocycline may increase the central nervous system depressant (CNS depressant) activities of Maprotiline.
Prochlorperazine	Prochlorperazine The risk or severity of adverse effects can be increased when Prochlorperazine is combined with Maprotiline.
Thioridazine	Thioridazine The metabolism of Maprotiline can be decreased when combined with Thioridazine.
Trifluoperazine	Trifluoperazine The risk or severity of adverse effects can be increased when Trifluoperazine is combined with Maprotiline.
Bleomycin	Bleomycin Bleomycin may decrease the excretion rate of Maprotiline which could result in a higher serum level.
Sulfadiazine	Sulfadiazine Sulfadiazine may decrease the excretion rate of Maprotiline which could result in a higher serum level.
Oxycodone	Oxycodone The risk or severity of adverse effects can be increased when Oxycodone is combined with Maprotiline.
Methadone	Methadone The risk or severity of adverse effects can be increased when Methadone is combined with Maprotiline.
Oxybutynin	Oxybutynin Maprotiline may increase the central nervous system depressant (CNS depressant) activities of Oxybutynin.
Benztropine	Benztropine Maprotiline may increase the central nervous system depressant (CNS depressant) activities of Benzatropine.
Ibuprofen	Ibuprofen Ibuprofen may decrease the excretion rate of Maprotiline which could result in a higher serum level.
Trihexyphenidyl	Trihexyphenidyl Maprotiline may increase the central nervous system depressant (CNS depressant) activities of Trihexyphenidyl.
Orphenadrine	Orphenadrine Maprotiline may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.
Perphenazine	Perphenazine The risk or severity of adverse effects can be increased when Perphenazine is combined with Maprotiline.
Azathioprine	Azathioprine The metabolism of Azathioprine can be decreased when combined with Maprotiline.
Fluphenazine	Fluphenazine The risk or severity of adverse effects can be increased when Fluphenazine is combined with Maprotiline.
Phentermine	Phentermine Phentermine may decrease the sedative and stimulatory activities of Maprotiline.
Methylphenidate	Methylphenidate Methylphenidate may decrease the excretion rate of Maprotiline which could result in a higher serum level.
Amoxapine	Amoxapine The metabolism of Maprotiline can be decreased when combined with Amoxapine.
Sulfasalazine	Sulfasalazine Sulfasalazine may decrease the excretion rate of Maprotiline which could result in a higher serum level.
Doxorubicin	Doxorubicin The metabolism of Maprotiline can be decreased when combined with Doxorubicin.
Mechlorethamine	Mechlorethamine The therapeutic efficacy of Maprotiline can be decreased when used in combination with Mechlorethamine.
Pyridostigmine	Pyridostigmine The therapeutic efficacy of Maprotiline can be decreased when used in combination with Pyridostigmine.
Phenazopyridine	Phenazopyridine Phenazopyridine may decrease the excretion rate of Maprotiline which could result in a higher serum level.
Carbamazepine	Carbamazepine The metabolism of Maprotiline can be increased when combined with Carbamazepine.
Molindone	Molindone The risk or severity of adverse effects can be increased when Maprotiline is combined with Molindone.
Methyldopa	Methyldopa Maprotiline may decrease the excretion rate of Methyldopa which could result in a higher serum level.
Clonidine	Clonidine The risk or severity of sedation can be increased when Clonidine is combined with Maprotiline.
Hydralazine	Hydralazine Maprotiline may decrease the excretion rate of Hydralazine which could result in a higher serum level.
Cimetidine	Cimetidine The metabolism of Maprotiline can be decreased when combined with Cimetidine.
Gentamicin Injection	Gentamicin Injection Gentamicin may decrease the excretion rate of Maprotiline which could result in a higher serum level.
Warfarin	Warfarin Maprotiline may decrease the excretion rate of Warfarin which could result in a higher serum level.
Clonazepam	Clonazepam Clonazepam may increase the central nervous system depressant (CNS depressant) activities of Maprotiline.
Loperamide	Loperamide The risk or severity of QTc prolongation can be increased when Maprotiline is combined with Loperamide.
Promethazine	Promethazine Maprotiline may increase the central nervous system depressant (CNS depressant) activities of Promethazine.
Meclofenamate	Meclofenamate Meclofenamic acid may decrease the excretion rate of Maprotiline which could result in a higher serum level.
Nitrofurantoin	Nitrofurantoin Nitrofurantoin may decrease the excretion rate of Maprotiline which could result in a higher serum level.
Griseofulvin	Griseofulvin The metabolism of Maprotiline can be increased when combined with Griseofulvin.
Digoxin	Digoxin Maprotiline may decrease the excretion rate of Digoxin which could result in a higher serum level.
Loxapine	Loxapine The risk or severity of adverse effects can be increased when Loxapine is combined with Maprotiline.
Chloroquine	Chloroquine The metabolism of Maprotiline can be decreased when combined with Chloroquine.
Quinine	Quinine The metabolism of Quinine can be decreased when combined with Maprotiline.
Ethosuximide	Ethosuximide Ethosuximide may increase the central nervous system depressant (CNS depressant) activities of Maprotiline.
Triamterene	Triamterene The metabolism of Maprotiline can be decreased when combined with Triamterene.
Lactulose	Lactulose The therapeutic efficacy of Lactulose can be decreased when used in combination with Maprotiline.
Chlorothiazide	Chlorothiazide Maprotiline may increase the excretion rate of Chlorothiazide which could result in a lower serum level and potentially a reduction in efficacy.
Chlorthalidone	Chlorthalidone Maprotiline may increase the excretion rate of Chlorthalidone which could result in a lower serum level and potentially a reduction in efficacy.
Metolazone	Metolazone Metolazone may increase the excretion rate of Maprotiline which could result in a lower serum level and potentially a reduction in efficacy.
Isosorbide	Isosorbide Isosorbide may increase the excretion rate of Maprotiline which could result in a lower serum level and potentially a reduction in efficacy.
Secobarbital	Secobarbital Secobarbital may increase the central nervous system depressant (CNS depressant) activities of Maprotiline.
Desipramine	Desipramine The metabolism of Desipramine can be decreased when combined with Maprotiline.
Amitriptyline	Amitriptyline The metabolism of Maprotiline can be decreased when combined with Amitriptyline.
Imipramine	Imipramine The metabolism of Maprotiline can be decreased when combined with Imipramine.
Probenecid	Probenecid Maprotiline may decrease the excretion rate of Probenecid which could result in a higher serum level.
Quinidine	Quinidine The metabolism of Quinidine can be decreased when combined with Maprotiline.
Procainamide	Procainamide The metabolism of Procainamide can be decreased when combined with Maprotiline.
Isoniazid	Isoniazid The metabolism of Maprotiline can be decreased when combined with Isoniazid.
Pyrazinamide	Pyrazinamide Pyrazinamide may decrease the excretion rate of Maprotiline which could result in a higher serum level.
Rifampin	Rifampin The metabolism of Maprotiline can be increased when combined with Rifampicin.
Disopyramide	Disopyramide The risk or severity of QTc prolongation can be increased when Maprotiline is combined with Disopyramide.
Valproic Acid	Valproic Acid The risk or severity of adverse effects can be increased when Valproic acid is combined with Maprotiline.
Tamoxifen	Tamoxifen The metabolism of Maprotiline can be decreased when combined with Tamoxifen.
Butabarbital	Butabarbital Butabarbital may increase the central nervous system depressant (CNS depressant) activities of Maprotiline.
Levothyroxine	Levothyroxine The risk or severity of adverse effects can be increased when Levothyroxine is combined with Maprotiline.
Liothyronine	Liothyronine Liothyronine may decrease the excretion rate of Maprotiline which could result in a higher serum level.
Methimazole	Methimazole The metabolism of Maprotiline can be decreased when combined with Methimazole.
Chlorpropamide	Chlorpropamide Chlorpropamide may decrease the excretion rate of Maprotiline which could result in a higher serum level.
Glucagon Injection	Glucagon Injection Maprotiline may increase the gastrointestinal motility reducing activities of Glucagon.
Tolbutamide	Tolbutamide Maprotiline may decrease the excretion rate of Tolbutamide which could result in a higher serum level.
Tolazamide	Tolazamide Tolazamide may decrease the excretion rate of Maprotiline which could result in a higher serum level.
Dextromethorphan	Dextromethorphan The risk or severity of adverse effects can be increased when Dextromethorphan is combined with Maprotiline.
Cyclobenzaprine	Cyclobenzaprine The risk or severity of CNS depression can be increased when Cyclobenzaprine is combined with Maprotiline.
Niacin	Niacin The metabolism of Maprotiline can be decreased when combined with Niacin.
Baclofen	Baclofen Baclofen may increase the central nervous system depressant (CNS depressant) activities of Maprotiline.
Doxylamine	Doxylamine Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Maprotiline.
Cyproheptadine	Cyproheptadine Cyproheptadine may increase the central nervous system depressant (CNS depressant) activities of Maprotiline.
Clemastine	Clemastine The risk or severity of QTc prolongation can be increased when Maprotiline is combined with Clemastine.
Chlorpheniramine	Chlorpheniramine The risk or severity of adverse effects can be increased when Maprotiline is combined with Chlorpheniramine.
Brompheniramine	Brompheniramine Dexbrompheniramine may increase the central nervous system depressant (CNS depressant) activities of Maprotiline.
Meclizine	Meclizine Meclizine may increase the central nervous system depressant (CNS depressant) activities of Maprotiline.
Ethambutol	Ethambutol Ethambutol may decrease the excretion rate of Maprotiline which could result in a higher serum level.
Methyclothiazide	Methyclothiazide Maprotiline may increase the excretion rate of Methyclothiazide which could result in a lower serum level and potentially a reduction in efficacy.
Hydrochlorothiazide	Hydrochlorothiazide Hydrochlorothiazide may decrease the excretion rate of Maprotiline which could result in a higher serum level.
Dantrolene	Dantrolene Dantrolene may increase the central nervous system depressant (CNS depressant) activities of Maprotiline.
Chlorzoxazone	Chlorzoxazone Chlorzoxazone may increase the central nervous system depressant (CNS depressant) activities of Maprotiline.
Carisoprodol	Carisoprodol The risk or severity of adverse effects can be increased when Carisoprodol is combined with Maprotiline.
Methocarbamol	Methocarbamol Methocarbamol may increase the central nervous system depressant (CNS depressant) activities of Maprotiline.
Pyridoxine	Pyridoxine Pyridoxine may decrease the excretion rate of Maprotiline which could result in a higher serum level.
Folic Acid	Folic Acid Folic acid may decrease the excretion rate of Maprotiline which could result in a higher serum level.
Disulfiram	Disulfiram The risk or severity of QTc prolongation can be increased when Disulfiram is combined with Maprotiline.
Propranolol (Cardiovascular)	Propranolol (Cardiovascular) The risk or severity of QTc prolongation can be increased when Maprotiline is combined with Propranolol.
Pseudoephedrine	Pseudoephedrine Pseudoephedrine may decrease the sedative and stimulatory activities of Maprotiline.
Nortriptyline	Nortriptyline The metabolism of Maprotiline can be decreased when combined with Nortriptyline.
Spironolactone	Spironolactone Spironolactone may increase the excretion rate of Maprotiline which could result in a lower serum level and potentially a reduction in efficacy.
Amphotericin B Injection	Amphotericin B Injection Amphotericin B may decrease the excretion rate of Maprotiline which could result in a higher serum level.
Phytonadione	Phytonadione Maprotiline may decrease the excretion rate of Phylloquinone which could result in a higher serum level.
Amikacin Injection	Amikacin Injection Amikacin may decrease the excretion rate of Maprotiline which could result in a higher serum level.
Nadolol	Nadolol Maprotiline may decrease the excretion rate of Nadolol which could result in a higher serum level.
Butorphanol Injection	Butorphanol Injection The risk or severity of adverse effects can be increased when Butorphanol is combined with Maprotiline.
Nalbuphine Injection	Nalbuphine Injection The risk or severity of adverse effects can be increased when Nalbuphine is combined with Maprotiline.
Allopurinol	Allopurinol Allopurinol may decrease the excretion rate of Maprotiline which could result in a higher serum level.
Oxytocin Injection	Oxytocin Injection The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Maprotiline.
Trimethobenzamide	Trimethobenzamide Trimethobenzamide may increase the central nervous system depressant (CNS depressant) activities of Maprotiline.
Flavoxate	Flavoxate Maprotiline may increase the central nervous system depressant (CNS depressant) activities of Flavoxate.
Papaverine	Papaverine The risk or severity of QTc prolongation can be increased when Maprotiline is combined with Papaverine.
Fluorouracil Injection	Fluorouracil Injection The risk or severity of QTc prolongation can be increased when Maprotiline is combined with Fluorouracil.
Colchicine	Colchicine Maprotiline may decrease the excretion rate of Colchicine which could result in a higher serum level.
Cefaclor	Cefaclor Cefaclor may decrease the excretion rate of Maprotiline which could result in a higher serum level.
Cefadroxil	Cefadroxil Cefadroxil may decrease the excretion rate of Maprotiline which could result in a higher serum level.
Cefazolin Injection	Cefazolin Injection Cefazolin may decrease the excretion rate of Maprotiline which could result in a higher serum level.
Cephalexin	Cephalexin Cephalexin may decrease the excretion rate of Maprotiline which could result in a higher serum level.
Cefoxitin Injection	Cefoxitin Injection Cefoxitin may decrease the excretion rate of Maprotiline which could result in a higher serum level.
Dacarbazine	Dacarbazine The metabolism of Maprotiline can be decreased when combined with Dacarbazine.
Acetazolamide	Acetazolamide Acetazolamide may increase the central nervous system depressant (CNS depressant) activities of Maprotiline.
Cefotaxime Injection	Cefotaxime Injection Cefotaxime may decrease the excretion rate of Maprotiline which could result in a higher serum level.
Calcitonin Salmon Injection	Calcitonin Salmon Injection Salmon calcitonin may decrease the excretion rate of Maprotiline which could result in a higher serum level.
Ketoconazole	Ketoconazole The metabolism of Maprotiline can be decreased when combined with Ketoconazole.
Pyrantel	Pyrantel Pyrantel may increase the central nervous system depressant (CNS depressant) activities of Maprotiline.
Thiotepa Injection	Thiotepa Injection The therapeutic efficacy of Maprotiline can be decreased when used in combination with Thiotepa.
Isoxsuprine	Isoxsuprine The risk or severity of Tachycardia can be increased when Maprotiline is combined with Isoxsuprine.
Vinblastine	Vinblastine The metabolism of Maprotiline can be decreased when combined with Vinblastine.
Ethacrynic Acid	Ethacrynic Acid Etacrynic acid may decrease the excretion rate of Maprotiline which could result in a higher serum level.
Colistimethate Injection	Colistimethate Injection Colistimethate may decrease the excretion rate of Maprotiline which could result in a higher serum level.
Metoprolol	Metoprolol The metabolism of Maprotiline can be decreased when combined with Metoprolol.
Hydroxyzine	Hydroxyzine The risk or severity of QTc prolongation can be increased when Hydroxyzine is combined with Maprotiline.
Thiothixene	Thiothixene The risk or severity of adverse effects can be increased when Maprotiline is combined with Thiothixene.
Aspirin	Aspirin Acetylsalicylic acid may decrease the excretion rate of Maprotiline which could result in a higher serum level.
Salsalate	Salsalate Salsalate may decrease the excretion rate of Maprotiline which could result in a higher serum level.
Alprazolam	Alprazolam The risk or severity of adverse effects can be increased when Alprazolam is combined with Maprotiline.
Temazepam	Temazepam The risk or severity of adverse effects can be increased when Temazepam is combined with Maprotiline.
Triazolam	Triazolam The risk or severity of adverse effects can be increased when Triazolam is combined with Maprotiline.
Dicyclomine	Dicyclomine Maprotiline may increase the central nervous system depressant (CNS depressant) activities of Dicyclomine.
Hyoscyamine	Hyoscyamine Maprotiline may increase the central nervous system depressant (CNS depressant) activities of Hyoscyamine.
Propantheline	Propantheline Maprotiline may increase the central nervous system depressant (CNS depressant) activities of Propantheline.
Trimethoprim	Trimethoprim Trimethoprim may decrease the excretion rate of Maprotiline which could result in a higher serum level.
Diltiazem	Diltiazem The risk or severity of QTc prolongation can be increased when Maprotiline is combined with Diltiazem.
Nifedipine	Nifedipine The risk or severity of QTc prolongation can be increased when Maprotiline is combined with Nifedipine.
Timolol	Timolol The risk or severity of QTc prolongation can be increased when Timolol is combined with Maprotiline.
Verapamil	Verapamil The metabolism of Maprotiline can be decreased when combined with Verapamil.
Atenolol	Atenolol The metabolism of Maprotiline can be decreased when combined with Atenolol.
Pindolol	Pindolol Maprotiline may increase the central nervous system depressant (CNS depressant) activities of Pindolol.
Cisplatin Injection	Cisplatin Injection Cisplatin may decrease the excretion rate of Maprotiline which could result in a higher serum level.
Diflunisal	Diflunisal Diflunisal may decrease the excretion rate of Maprotiline which could result in a higher serum level.
Piroxicam	Piroxicam Piroxicam may decrease the excretion rate of Maprotiline which could result in a higher serum level.
Bumetanide	Bumetanide Bumetanide may increase the excretion rate of Maprotiline which could result in a lower serum level and potentially a reduction in efficacy.
Streptozocin	Streptozocin The metabolism of Maprotiline can be increased when combined with Streptozocin.
Etoposide	Etoposide The metabolism of Maprotiline can be decreased when combined with Etoposide.
Glipizide	Glipizide Maprotiline may decrease the excretion rate of Glipizide which could result in a higher serum level.
Indapamide	Indapamide Indapamide may increase the excretion rate of Maprotiline which could result in a lower serum level and potentially a reduction in efficacy.
Amoxicillin	Amoxicillin Maprotiline may decrease the excretion rate of Amoxicillin which could result in a higher serum level.
Nafcillin Injection	Nafcillin Injection The metabolism of Maprotiline can be increased when combined with Nafcillin.
Oxacillin Injection	Oxacillin Injection Oxacillin may decrease the excretion rate of Maprotiline which could result in a higher serum level.
Pentoxifylline	Pentoxifylline The metabolism of Maprotiline can be decreased when combined with Pentoxifylline.
Pentamidine Injection	Pentamidine Injection The risk or severity of QTc prolongation can be increased when Maprotiline is combined with Pentamidine.
Ceftriaxone Injection	Ceftriaxone Injection Ceftriaxone may decrease the excretion rate of Maprotiline which could result in a higher serum level.
Labetalol	Labetalol The metabolism of Maprotiline can be decreased when combined with Labetalol.
Auranofin	Auranofin Maprotiline may decrease the excretion rate of Auranofin which could result in a higher serum level.
Leuprolide Injection	Leuprolide Injection The risk or severity of QTc prolongation can be increased when Maprotiline is combined with Leuprolide.
Gemfibrozil	Gemfibrozil The metabolism of Maprotiline can be decreased when combined with Gemfibrozil.
Guanabenz	Guanabenz The metabolism of Maprotiline can be decreased when combined with Guanabenz.
Dipivefrin Ophthalmic	Dipivefrin Ophthalmic Adefovir dipivoxil may decrease the excretion rate of Maprotiline which could result in a higher serum level.
Ceftazidime Injection	Ceftazidime Injection Ceftazidime may decrease the excretion rate of Maprotiline which could result in a higher serum level.
Ketoprofen	Ketoprofen Ketoprofen may decrease the excretion rate of Maprotiline which could result in a higher serum level.
Cefotetan Injection	Cefotetan Injection Cefotetan may decrease the excretion rate of Maprotiline which could result in a higher serum level.
Pimozide	Pimozide The metabolism of Pimozide can be decreased when combined with Maprotiline.
Flurbiprofen	Flurbiprofen Flurbiprofen may decrease the excretion rate of Maprotiline which could result in a higher serum level.
Amiodarone	Amiodarone The metabolism of Maprotiline can be decreased when combined with Amiodarone.
Aztreonam Injection	Aztreonam Injection Aztreonam may decrease the excretion rate of Maprotiline which could result in a higher serum level.
Buspirone	Buspirone The risk or severity of serotonin syndrome can be increased when Buspirone is combined with Maprotiline.
Lovastatin	Lovastatin The metabolism of Maprotiline can be decreased when combined with Lovastatin.
Ciprofloxacin	Ciprofloxacin The metabolism of Maprotiline can be decreased when combined with Ciprofloxacin.
Mesalamine	Mesalamine Mesalazine may decrease the excretion rate of Maprotiline which could result in a higher serum level.
Diclofenac	Diclofenac Diclofenac may decrease the excretion rate of Maprotiline which could result in a higher serum level.
Fluoxetine	Fluoxetine The serum concentration of Maprotiline can be increased when it is combined with Fluoxetine.
Nimodipine	Nimodipine The risk or severity of QTc prolongation can be increased when Maprotiline is combined with Nimodipine.
Interferon Alfa-2b Injection	Interferon Alfa-2b Injection The metabolism of Maprotiline can be decreased when combined with Interferon alfa-2b.
Clozapine	Clozapine The metabolism of Maprotiline can be decreased when combined with Clozapine.
Estazolam	Estazolam The risk or severity of adverse effects can be increased when Maprotiline is combined with Estazolam.
Idarubicin	Idarubicin The metabolism of Idarubicin can be decreased when combined with Maprotiline.
Ofloxacin	Ofloxacin The risk or severity of QTc prolongation can be increased when Maprotiline is combined with Ofloxacin.
Didanosine	Didanosine Didanosine may decrease the excretion rate of Maprotiline which could result in a higher serum level.
Pentostatin Injection	Pentostatin Injection Pentostatin may decrease the excretion rate of Maprotiline which could result in a higher serum level.
Clarithromycin	Clarithromycin The risk or severity of QTc prolongation can be increased when Maprotiline is combined with Clarithromycin.
Etodolac	Etodolac Etodolac may decrease the excretion rate of Maprotiline which could result in a higher serum level.
Felodipine	Felodipine The metabolism of Felodipine can be decreased when combined with Maprotiline.
Fosinopril	Fosinopril Fosinopril may decrease the excretion rate of Maprotiline which could result in a higher serum level.
Nabumetone	Nabumetone Nabumetone may decrease the excretion rate of Maprotiline which could result in a higher serum level.
Simvastatin	Simvastatin The metabolism of Maprotiline can be decreased when combined with Simvastatin.
Itraconazole	Itraconazole The risk or severity of QTc prolongation can be increased when Maprotiline is combined with Itraconazole.
Lisinopril	Lisinopril Lisinopril may decrease the excretion rate of Maprotiline which could result in a higher serum level.
Oxaprozin	Oxaprozin Oxaprozin may decrease the excretion rate of Maprotiline which could result in a higher serum level.
Sotalol	Sotalol The metabolism of Sotalol can be decreased when combined with Maprotiline.
Bisoprolol	Bisoprolol Bisoprolol may decrease the excretion rate of Maprotiline which could result in a higher serum level.
Zolpidem	Zolpidem Maprotiline may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.
Doxazosin	Doxazosin The metabolism of Maprotiline can be decreased when combined with Doxazosin.
Isradipine	Isradipine The risk or severity of QTc prolongation can be increased when Isradipine is combined with Maprotiline.
Omeprazole	Omeprazole The metabolism of Maprotiline can be increased when combined with Omeprazole.
Cisapride	Cisapride The metabolism of Maprotiline can be decreased when combined with Cisapride.
Gabapentin	Gabapentin The risk or severity of adverse effects can be increased when Maprotiline is combined with Gabapentin.
Fluvastatin	Fluvastatin The metabolism of Fluvastatin can be decreased when combined with Maprotiline.
Venlafaxine	Venlafaxine The metabolism of Maprotiline can be decreased when combined with Venlafaxine.
Nizatidine	Nizatidine The therapeutic efficacy of Maprotiline can be decreased when used in combination with Nizatidine.
Fluvoxamine	Fluvoxamine The metabolism of Maprotiline can be decreased when combined with Fluvoxamine.
Nefazodone	Nefazodone The risk or severity of adverse effects can be increased when Maprotiline is combined with Nefazodone.
Lamotrigine	Lamotrigine The risk or severity of adverse effects can be increased when Lamotrigine is combined with Maprotiline.
Losartan	Losartan The risk or severity of QTc prolongation can be increased when Losartan is combined with Maprotiline.
Valacyclovir	Valacyclovir Valaciclovir may decrease the excretion rate of Maprotiline which could result in a higher serum level.
Tramadol	Tramadol The risk or severity of serotonin syndrome can be increased when Tramadol is combined with Maprotiline.
Vinorelbine Injection	Vinorelbine Injection The metabolism of Maprotiline can be decreased when combined with Vinorelbine.
Carboplatin Injection	Carboplatin Injection Carboplatin may decrease the excretion rate of Maprotiline which could result in a higher serum level.
Moexipril	Moexipril The risk or severity of QTc prolongation can be increased when Moexipril is combined with Maprotiline.
Lansoprazole	Lansoprazole The metabolism of Maprotiline can be decreased when combined with Lansoprazole.
Ifosfamide Injection	Ifosfamide Injection Maprotiline may decrease the excretion rate of Ifosfamide which could result in a higher serum level.
Nicardipine	Nicardipine The metabolism of Maprotiline can be decreased when combined with Nicardipine.
Bupropion	Bupropion The risk or severity of seizure can be increased when Maprotiline is combined with Bupropion.
Ticlopidine	Ticlopidine The metabolism of Maprotiline can be decreased when combined with Ticlopidine.
Saquinavir	Saquinavir The risk or severity of QTc prolongation can be increased when Maprotiline is combined with Saquinavir.
Metformin	Metformin Metformin may decrease the excretion rate of Maprotiline which could result in a higher serum level.
Nisoldipine	Nisoldipine Nisoldipine may decrease the excretion rate of Maprotiline which could result in a higher serum level.
Lamivudine	Lamivudine Lamivudine may decrease the excretion rate of Maprotiline which could result in a higher serum level.
Riluzole	Riluzole Riluzole may increase the central nervous system depressant (CNS depressant) activities of Maprotiline.
Acarbose	Acarbose Acarbose may decrease the excretion rate of Maprotiline which could result in a higher serum level.
Gemcitabine Injection	Gemcitabine Injection Gemcitabine may decrease the excretion rate of Maprotiline which could result in a higher serum level.
Ritonavir	Ritonavir The metabolism of Maprotiline can be decreased when combined with Ritonavir.
Cidofovir Injection	Cidofovir Injection Cidofovir may decrease the excretion rate of Maprotiline which could result in a higher serum level.
Meropenem Injection	Meropenem Injection Meropenem may decrease the excretion rate of Maprotiline which could result in a higher serum level.
Clomipramine	Clomipramine The metabolism of Maprotiline can be decreased when combined with Clomipramine.
Zafirlukast	Zafirlukast The metabolism of Maprotiline can be decreased when combined with Zafirlukast.
Fosfomycin	Fosfomycin Fosfomycin may decrease the excretion rate of Maprotiline which could result in a higher serum level.
Mirtazapine	Mirtazapine Maprotiline may increase the serotonergic activities of Mirtazapine.
Topiramate	Topiramate The risk or severity of hyperthermia and oligohydrosis can be increased when Maprotiline is combined with Topiramate.
Zileuton	Zileuton The metabolism of Maprotiline can be decreased when combined with Zileuton.
Insulin Lispro Injection	Insulin Lispro Injection The metabolism of Maprotiline can be increased when combined with Insulin lispro.
Pramipexole	Pramipexole Maprotiline may increase the sedative activities of Pramipexole.
Donepezil	Donepezil The therapeutic efficacy of Maprotiline can be decreased when used in combination with Donepezil.
Nelfinavir	Nelfinavir The metabolism of Maprotiline can be decreased when combined with Nelfinavir.
Azithromycin	Azithromycin The risk or severity of QTc prolongation can be increased when Maprotiline is combined with Azithromycin.
Loratadine	Loratadine Maprotiline may increase the anticholinergic activities of Loratadine.
Carvedilol	Carvedilol The metabolism of Carvedilol can be decreased when combined with Maprotiline.
Nilutamide	Nilutamide Nilutamide may decrease the excretion rate of Maprotiline which could result in a higher serum level.
Flutamide	Flutamide The metabolism of Maprotiline can be decreased when combined with Flutamide.
Selegiline	Selegiline The risk or severity of adverse effects can be increased when Maprotiline is combined with Selegiline.
Bicalutamide	Bicalutamide The metabolism of Maprotiline can be decreased when combined with Bicalutamide.
Sertraline	Sertraline The risk or severity of adverse effects can be increased when Maprotiline is combined with Sertraline.
Propafenone	Propafenone The metabolism of Maprotiline can be decreased when combined with Propafenone.
Tamsulosin	Tamsulosin Tamsulosin may decrease the excretion rate of Maprotiline which could result in a higher serum level.
Ropinirole	Ropinirole Maprotiline may increase the sedative activities of Ropinirole.
Quetiapine	Quetiapine The risk or severity of adverse effects can be increased when Maprotiline is combined with Quetiapine.
Cefepime Injection	Cefepime Injection Cefepime may decrease the excretion rate of Maprotiline which could result in a higher serum level.
Cefprozil	Cefprozil Cefprozil may decrease the excretion rate of Maprotiline which could result in a higher serum level.
Cefpodoxime	Cefpodoxime Cefpodoxime may decrease the excretion rate of Maprotiline which could result in a higher serum level.
Cetirizine	Cetirizine Cetirizine may increase the central nervous system depressant (CNS depressant) activities of Maprotiline.
Paroxetine	Paroxetine The metabolism of Maprotiline can be decreased when combined with Paroxetine.
Tolcapone	Tolcapone Tolcapone may increase the central nervous system depressant (CNS depressant) activities of Maprotiline.
Citalopram	Citalopram The risk or severity of adverse effects can be increased when Citalopram is combined with Maprotiline.
Capecitabine	Capecitabine Maprotiline may decrease the excretion rate of Capecitabine which could result in a higher serum level.
Efavirenz	Efavirenz The metabolism of Maprotiline can be decreased when combined with Efavirenz.
Abacavir	Abacavir Maprotiline may decrease the excretion rate of Abacavir which could result in a higher serum level.
Sildenafil	Sildenafil The metabolism of Maprotiline can be decreased when combined with Sildenafil.
Celecoxib	Celecoxib The metabolism of Maprotiline can be decreased when combined with Celecoxib.
Rosiglitazone	Rosiglitazone The metabolism of Maprotiline can be decreased when combined with Rosiglitazone.
Tolterodine	Tolterodine Maprotiline may increase the central nervous system depressant (CNS depressant) activities of Tolterodine.
Thalidomide	Thalidomide Maprotiline may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.
Oseltamivir	Oseltamivir Oseltamivir may decrease the excretion rate of Maprotiline which could result in a higher serum level.
Balsalazide	Balsalazide Balsalazide may decrease the excretion rate of Maprotiline which could result in a higher serum level.
Nateglinide	Nateglinide Nateglinide may decrease the excretion rate of Maprotiline which could result in a higher serum level.
Galantamine	Galantamine The risk or severity of QTc prolongation can be increased when Galantamine is combined with Maprotiline.
Levetiracetam	Levetiracetam Levetiracetam may increase the central nervous system depressant (CNS depressant) activities of Maprotiline.
Rabeprazole	Rabeprazole The metabolism of Rabeprazole can be increased when combined with Maprotiline.
Terbinafine	Terbinafine The metabolism of Maprotiline can be decreased when combined with Terbinafine.

Maprotiline

On this page